rilpivirine (Edurant, RPV)
Jump to navigation
Jump to search
Introduction
FDA-approved May 2011
Indications
- treatment-naive HIV1
- for use in combination with other antiretroviral drugs
Contraindications
- use during pregnancy (data insufficiency)[2]
- concurrent use of proton pump inhibitor[3]
Dosage
* requires food & gastric acid for absorption[3]
Adverse effects
- depression
- insomnia
- headache
- rash
- allegedly fewer adverse effects than efavirenz
- drug adverse effects of antiretroviral agents
- drug adverse effects of non-nucleoside reverse transcriptase inhibitors (NNRTI)
Drug interactions
- proton pump inhibitors interfere with absorption[3]
Laboratory
Mechanism of action
- inhibits viral reverse transcriptase
- blocks HIV1 viral replication
More general terms
Component of
- cabotegravir/rilpivirine (Cabenuva)
- dolutegravir/rilpivirine (Juluca)
- emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF, TAF/FTC/RPV, Complera, Odefsey)
References
- ↑ FDA NEWS RELEASE: May 20, 2011 FDA approves new HIV treatment http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256087.htm
- ↑ 2.0 2.1 Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016) - ↑ 3.0 3.1 3.2 3.3 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015